Suven Life Sciences trades with traction on the bourses

17 Jul 2015 Evaluate

Suven Life Sciences is currently trading at Rs. 270.00, up by 5.15 points or 1.94% from its previous closing of Rs. 264.85 on the BSE.

The scrip opened at Rs. 266.50 and has touched a high and low of Rs. 272.95 and Rs. 265.40 respectively. So far 92673 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 105.00 on 28-Jul-2014.

Last one week high and low of the scrip stood at Rs. 272.95 and Rs. 233.80 respectively. The current market cap of the company is Rs. 3428.35 crore.

The promoters holding in the company stood at 59.44% while Institutions and Non-Institutions held 7.49% and 33.06% respectively.

Several exciting new results and data presentations from Suven Life Science’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Alzheimer's Association International Conference (AAIC) being held in Washington DC, USA during July 18-23, 2015. AAIC is the world's largest conference of its kind, where thousands of researchers from more than 70 countries will gather to reveal the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.

Alzheimer’s disease is one of the scourges of modern day health care which is the largest and fastest growing unmet medical need and Suven is in the forefront of developing a drug for the treatment of this debilitating disease. Alzheimer’s is not just a memory loss as everyone thinks but Alzheimer’s kills. Alzheimer’s is the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression.

Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer’s disease but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders and major depressive disorder.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

 

Suven Life Sciences Share Price

163.05 -3.00 (-1.81%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×